Περίληψη:
The purpose of this study was to investigate the use of naproxen in patients with paraneoplastic fever. In total, 82 patients were entered in this trial. Tumours diagnosed histologically were: breast 12, testes 2, colorectal 16, lung 15, head and neck 13, renal 6, unknown origin 8, pancreas 3, ovarian 2, cervix uteri 2, gastric 3, melanomas 2 and sarcomas 2. A clinical methodology was followed in order to exclude any possibility of infection. After 5 days of persistent unexplained fever >38°C without any incidence of infection and despite adequate antibiotic treatment, the fever was attributed to the malignancy and patients were treated with oral naproxen 250mg twice a day at 12-hourly intervals. Fever was monitored for 10 days after initiation of treatment with naproxen. Of the 82 patients who received this drug, 18 patients (22%) did not respond to therapy. We then re-evaluated those 18 patients for the possibility of infection: 6 were found to suffer from microbial infections, and 8 received new empiric antibiotic treatment; of these 8, 4 responded. Among the remaining 4 nonresponders, one was found to have a rectal abscess, and the other 3 died shortly afterwards; we were thus unable to follow them up completely. We therefore concluded that the use of nonsteroidal anti-inflammatory drugs, particularly naproxen, in the treatment of paraneoplastic fever is successful in 78% of patients. The persistence of fever in patients who received naproxen might be attributed to an infectious cause. © 1995, Adis International Limited. All rights reserved.
Συγγραφείς:
Tsavaris, N.
Mylonakis, N.
Bacoyiannis, Ch.
Karvounis, N.
Kordossis, T.
Daliani, D.
Karabelis, A.
Kosmidis, P.
Λέξεις-κλειδιά:
amoxicillin plus clavulanic acid; antibiotic agent; carbenicillin; cefaclor; cefamandole; cefotaxime; cefoxitin; ceftriaxone; cefuroxime; cotrimoxazole; gentamicin; naproxen; nonsteroid antiinflammatory agent; tobramycin, article; breast tumor; clinical trial; colorectal tumor; fever; head tumor; human; human cell; infection; kidney tumor; lung tumor; major clinical study; melanoma; methodology; oral drug administration; ovary tumor; pancreas tumor; paraneoplastic syndrome; patient monitoring; priority journal; sarcoma; stomach tumor; testis tumor; uterine cervix tumor
